PolyPid (NASDAQ:PYPD) Trading Down 0.3%

Shares of PolyPid Ltd. (NASDAQ:PYPDGet Free Report) traded down 0.3% on Wednesday . The company traded as low as $4.53 and last traded at $4.78. 4,404 shares traded hands during trading, a decline of 39% from the average session volume of 7,217 shares. The stock had previously closed at $4.80.

PolyPid Stock Down 0.3 %

The stock has a market capitalization of $22.94 million, a price-to-earnings ratio of -0.24 and a beta of 1.41. The firm has a 50 day simple moving average of $5.71 and a 200-day simple moving average of $5.06. The company has a debt-to-equity ratio of 2.17, a current ratio of 0.83 and a quick ratio of 0.83.

PolyPid (NASDAQ:PYPDGet Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($3.97) earnings per share for the quarter, missing the consensus estimate of ($2.17) by ($1.80). On average, sell-side analysts forecast that PolyPid Ltd. will post -3.72 EPS for the current fiscal year.

Institutional Investors Weigh In On PolyPid

Several hedge funds have recently bought and sold shares of PYPD. UBS Group AG raised its stake in shares of PolyPid by 29.9% during the 1st quarter. UBS Group AG now owns 285,399 shares of the company’s stock worth $1,558,000 after purchasing an additional 65,746 shares in the last quarter. Silverarc Capital Management LLC raised its position in PolyPid by 1.2% during the first quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock worth $1,191,000 after acquiring an additional 2,555 shares in the last quarter. Boothbay Fund Management LLC raised its position in PolyPid by 514.5% during the first quarter. Boothbay Fund Management LLC now owns 122,898 shares of the company’s stock worth $57,000 after acquiring an additional 102,898 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in PolyPid by 83.3% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 52,251 shares of the company’s stock valued at $285,000 after acquiring an additional 23,752 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of PolyPid in the 1st quarter valued at about $72,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Company Profile

(Get Free Report)

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.

Recommended Stories

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.